Vaccination against zoster remains effective in older adults who later undergo chemotherapy

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 913-919

  Tseng, Hung Fu ^a   Tartof, Sara ^a   Harpaz, Rafael ^b   Luo, Yi ^a   Sy, Lina S ^a   Hetcher, Rulin C ^a   Jacobsen, Steven J ^a  

^a KAISER PERMANENTE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Chemotherapy; Immunosuppression; Vaccine effectiveness; Zoster vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VACCINATION; COMPLICATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; NEOPLASMS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALIFORNIA; COHORT STUDIES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84921047899     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu498     Document Type: Article

References (25)

1. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr 2012; 61:203-7.
2. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res 2013; 65:854-61.
3. Ranganathan P. Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors. Ann RheumDis 2013; 72:e4.
4. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737-44.
5. Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13:15-23.
6. Berman JN,Wang M, BerryW, Neuberg DS, Guinan EC. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant 2006; 37:73-80.
7. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991; 7:435-7.
8. Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 2013; 22:82-90.
9. Dunst J, Steil B, Furch S, Fach A, Bormann G, MarschW. Herpes zoster in breast cancer patients after radiotherapy. Strahlenther Onkol 2000; 176:513-6.
10. Gnann JW, Whitley RJ. Natural history and treatment of varicellazoster in high-risk populations. J Hosp Infect 1991; 18(suppl A): 317-29.
11. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10:e1001420.
12. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160-6.
13. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
14. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4.
15. Tseng HF, Schmid DS, Harpaz R, et al. Herpes zoster caused by vaccine strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis 2014; 58:1125-8.
16. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012; 16:37-41.
17. Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2006; 12:143-54.
18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines). Prevention and treatment of cancer-related infections. Version I. Fort Washington, Pennsylvania: National Comprehensive Cancer Network, 2013.
19. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43-9.
20. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations): lifetime risk of being diagnosed with cancer, 2014. Available at: http:// seer.cancer.gov/csr/1975-2010/results-merged/topic-lifetime-risk.pdf. Accessed 24 February 2014.
21. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and posther-petic neuralgia in older adults. Vaccine 2007; 25:8326-37.
22. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882-7.
23. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011; 174: 1054-61.
24. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.
25. Tseng HF, Schmid DS, Harpaz R, et al. Assessment of the accuracy of clinical diagnosis of herpes zoster by polymerase chain reaction. In: IDWeek 2013, San Francisco, CA, 2013.